^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    MDM2-p53 antagonist

    Related drugs:
    Apply
    A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma (NCT05376800)
    Phase 1
    Boehringer Ingelheim
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    11/07/2022
    Primary completion :
    08/29/2025
    Completion :
    08/29/2025
    TP53
    |
    TP53 wild-type • IDH wild-type
    |
    brigimadlin (BI 907828)
    This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) (NCT03449381)
    Phase 1
    Boehringer Ingelheim
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    06/20/2018
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    TP53 • MDM2
    |
    TP53 wild-type
    |
    brigimadlin (BI 907828)
    Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder (NCT05512377)
    Phase 2
    Boehringer Ingelheim
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    12/13/2022
    Primary completion :
    06/10/2025
    Completion :
    06/10/2025
    TP53 • MDM2
    |
    TP53 wild-type
    |
    brigimadlin (BI 907828)
    Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma (NCT06058793)
    Phase 3
    Boehringer Ingelheim
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    12/13/2023
    Primary completion :
    07/07/2025
    Completion :
    07/07/2025
    MDM2
    |
    MDM2 amplification
    |
    brigimadlin (BI 907828)
    A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor (NCT05372367)
    Phase 1
    Boehringer Ingelheim
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    08/11/2022
    Primary completion :
    07/17/2024
    Completion :
    06/13/2025
    TP53
    |
    TP53 wild-type
    |
    brigimadlin (BI 907828) • itraconazole • rifampicin
    A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (NCT03964233)
    Phase 1
    Boehringer Ingelheim
    Active, not recruiting
    Last update posted :
    06/11/2024
    Initiation :
    06/11/2019
    Primary completion :
    09/03/2024
    Completion :
    05/30/2026
    TP53 • MDM2
    |
    TP53 mutation • TP53 wild-type • TP53 amplification
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
    Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma (NCT05218499)
    Phase 2/3
    Boehringer Ingelheim
    Active, not recruiting
    Last update posted :
    05/22/2024
    Initiation :
    03/25/2022
    Primary completion :
    04/16/2024
    Completion :
    05/27/2026
    MDM2
    |
    MDM2 amplification
    |
    doxorubicin hydrochloride • brigimadlin (BI 907828)
    Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures (EMPIRE) (NCT06084689)
    Phase 2
    Institut Bergonié
    Not yet recruiting
    Last update posted :
    10/20/2023
    Initiation :
    01/01/2024
    Primary completion :
    07/01/2026
    Completion :
    01/01/2027
    PD-L1 • TP53
    |
    TP53 wild-type
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091)